Full Text View
Tabular View
No Study Results Posted
Related Studies
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Cantonal Hospital of St. Gallen.
Recruitment status was  Recruiting
Study NCT00917839   Information provided by Cantonal Hospital of St. Gallen

First Received on June 9, 2009.   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
lamotrigine
Additional drug interventions recognized in this trial
Interferon beta 1a
Interferon-beta
Interferons
Neuroprotective Agents
More general drug interventions related to this trial
Adjuvants, Immunologic
Anti-Infective Agents
Anticonvulsants
Antineoplastic Agents
Antiviral Agents
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Immunologic Factors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Cantonal Hospital of St. Gallen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services